Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Sotatercept

Generic Name: Sotatercept

Brand Names: Winrevair

Drug Type: Biotech

CAS Number: 1001080-50-7

Unique Ingredient Identifier: 0QI90BTJ37

Overview

Sotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others.

Background

Sotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Right Ventricular Compensation with Sotatercept: a Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)

Phase 4

Not yet recruiting

Posted: 2024/10/26

Sponsor:

Amsterdam UMC, locat...

ID:NCT06658522

Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension

Phase 4

Recruiting

Posted: 2024/05/10

Sponsor:Mayo Clinic

ID:NCT06409026

A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)

Phase 3

Active, not recruiting

Posted: 2023/04/18

Sponsor:Merck Sharp & Dohme ...

ID:NCT05818137

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

Phase 2

Recruiting

Posted: 2022/10/20

Sponsor:Merck Sharp & Dohme ...

ID:NCT05587712

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

Phase 2

Active, not recruiting

Posted: 2021/06/30

Sponsor:

Acceleron Pharma, In...

ID:NCT04945460

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

ATS 2025 Conference to Showcase Groundbreaking Pulmonary Research and Patient-Centered Initiatives

10 days ago

The American Thoracic Society (ATS) 2025 International Conference in San Francisco will feature cutting-edge research across pulmonary, critical care, and sleep medicine, drawing over 10,000 attendees from 85 countries.

CDMO Market Report: Key Regulatory Approvals and Clinical Advances in March-April 2025

a month ago

Multiple CDMOs secured significant contract manufacturing opportunities as regulatory bodies approved new indications for established drugs, particularly in oncology and rare diseases.

Merck's WINREVAIR Shows Promising Phase 3 Results for Pulmonary Arterial Hypertension Treatment

2 months ago

Merck's Phase 3 ZENITH trial for WINREVAIR demonstrated promising results for treating pulmonary arterial hypertension, adding to the company's growing therapeutic portfolio.

Merck to Present Phase 3 ZENITH Trial Results for WINREVAIR in High-Risk PAH Patients at ACC.25

2 months ago

Merck will present late-breaking data from the Phase 3 ZENITH trial evaluating WINREVAIR (sotatercept-csrk) in high-risk pulmonary arterial hypertension patients, which was concluded early due to overwhelming efficacy.

Pharmaceutical Industry Braces for $236 Billion Patent Cliff by 2030: Strategic Responses from Major Players

3 months ago

The global pharmaceutical industry faces a $236 billion patent cliff between 2025-2030, with nearly 70 blockbuster drugs losing exclusivity and exposing major companies to significant revenue losses.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy